66 / 69
66
83.
Redaelli S, Piazza R, Rostagno R, Magistroni V, Perini P,
Marega M, et al. Activity of bosutinib, dasatinib, and
nilotinib against 18 imatinib-resistant BCR/ABL mutants. J
Clin Oncol 2009;27:469-71.
84.
Hughes T, Saglio G, Branford S, Soverini S, Kim DW,
Müller MC, et al. Impact of baseline BCR-ABL mutations
on response to nilotinib in patients with chronic myeloid
leukemia in chronic phase. J Clin Oncol 2009;27:4204-10.
85.
Branford S, Melo JV, Hughes TP. Selecting optimal second-
line tyrosine kinase inhibitor therapy for chronic myeloid
leukemia patients after imatinib failure: does the BCR-ABL
mutation status really matter? Blood 2009;114:5426-35.
86.
Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS,
Hughes TP, et al. Sensitive detection of BCR-ABL1
mutations in patients with chronic myeloid leukemia after
imatinib resistance is predictive of outcome during
subsequent therapy. J Clin Oncol 2011;29:4250-9.
87.
Wang L, Pearson K, Pillitteri L, Ferguson JE, Clark RE.
Serial monitoring of BCR-ABL by peripheral blood real-
time polymerase chain reaction predicts the marrow
cytogenetic response to imatinib mesylate in chronic
myeloid leukaemia. Br J Haematol 2002;118:771-7.
88.
Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A,
Hensley ML, et al. Frequency of Major Molecular
Responses to Imatinib or Interferon Alfa plus Cytarabine
in Newly Diagnosed Chronic Myeloid Leukemia N Engl J
Med 2003;349:1423-32.
89.
Lange T, Bumm T, Otto S, Al-Ali HK, Kovacs I, Krug D, et
al. Quantitative reverse transcription polymerase chain
reaction should not replace conventional cytogenetics for
monitoring patients with chronic myeloid leukemia
during early phase of imatinib therapy. Haematologica
2004;89:49-57.